Universitätsklinikum Magdeburg A.ö.R.

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP) (2017) Offenmüller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Classen CF, et al. Journal article Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation (2017) Chatzikyrkou C, Eichler J, Karch A, Clajus C, Scurt FG, Ramackers W, Lehner F, et al. Journal article The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals (2017) Hinderer M, Boeker M, Wagner SA, Binder H, Sckert F, Newe S, Huelsemann JL, et al. Journal article "TORNADO" - Theranostic One-Step RNA Detector; microfluidic disc for the direct detection of microRNA-134 in plasma and cerebrospinal fluid (2017) Mcardle H, Jimenez-Mateos EM, Raoof R, Carthy E, Boyle D, Elnaggar H, Delanty N, et al. Journal article Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus (2017) Raoof R, Jimenez-Mateos EM, Bauer S, Tackenberg B, Rosenow F, Lang J, Onugoren MD, et al. Journal article Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial (2017) Einsele H, Engelhardt M, Tapprich C, Mueller J, Liebisch P, Langer C, Kropff M, et al. Journal article Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development (2017) Hinderer M, Boeker M, Wagner SA, Lablans M, Newe S, Huelsemann JL, Neumaier M, et al. Journal article The Summer School of the German Society for Orthopaedics and Traumatology - A Success Story (2016) Merschin D, Mutschler M, Stange R, Kopschina C, Schuettrumpf P, Doepfer AK, Achatz G, et al. Journal article Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article